Cai Jing Wang·2026-01-30 07:33Core Viewpoint - The strategic collaboration between the company and AstraZeneca aims to leverage the company's sustained-release drug delivery technology and AI discovery platform for innovative long-acting peptide drugs [1] Group 1: Strategic Collaboration - The agreement includes comprehensive strategic cooperation, advancing the existing clinical pipeline of long-acting peptides, and discovering and developing other innovative long-acting peptide products for AstraZeneca [1] - AstraZeneca will receive global exclusive rights to the company's monthly injectable weight management product portfolio, which includes one clinical-ready project, SYH2082, and three projects in the preclinical stage [1] Group 2: Financial Terms - The company will receive a $1.2 billion upfront payment and is entitled to up to $3.5 billion in potential research milestone payments and up to $13.8 billion in potential sales milestone payments [1] - Additionally, the company will receive a sales commission of up to a double-digit percentage based on the annual net sales of the licensed products [1]